Background: Owing to its ability to form spores and toxins, Bacillus anthracis is considered a bioterror agent. Although current therapeutic strategies can be effective, treatment does not prevent sporulation and toxin production.
Introduction
Bacillus anthracis (anthrax) is a sporulating bacterium that can be transmitted via contact, ingestion and aerosolization. 1 Pathogenesis is attributed to two exotoxins and a capsule, encoded on the pXO1and pXO2 plasmids, respectively, which are essential for full virulence. 2 A 60 day course of antibiotics is recommended when anthrax exposure is suspected. 1 Delays in treatment allow toxin accumulation in the body and the rate of survival decreases dramatically. Moreover, antibiotic-resistant strains can be bioengineered with ease. 3 Therefore, better therapeutics are required.
Recently, levofloxacin, a bactericidal agent that targets DNA replication, was approved as an alternative for treating anthrax. 4, 5 Additionally, linezolid, a protein synthesis inhibitor, has been suggested as a possible alternative for treating anthrax. 6, 7 To date, the combined effect of levofloxacin with linezolid on B. anthracis growth, sporulation and toxin production has not been examined. To test the hypothesis that combination treatment (a bactericidal agent + protein synthesis inhibitor) would be the most effective therapy for killing B. anthracis and preventing toxin and spore production, static and continuous medium replacement models were used.
Materials and methods

Microorganisms
Two B. anthracis isolates, a fully virulent clinical strain (03-0191) and the pXO2-deficient Sterne strain, were acquired from the National Microbiology Laboratory (NML). All studies were performed in a Biosafety Level 3 laboratory at the NML. Samples from 2808C glycerol stocks (10 9 spores/mL) were resurrected by streaking on an LB-Miller plate and incubated overnight at 378C.
For bacterial suspension, colonies were suspended in magnesium and calcium CAMHB. 8 Suspensions were adjusted to contain 10 5 cfu/mL using a 0.5 McFarland standard (Thermo Scientific, Ontario). All studies were performed in triplicate.
Antibiotics
Levofloxacin (Hospira Incorporated, GA, USA) and linezolid (Pfizer Canada, Quebec) were purchased from St Boniface Hospital (Winnipeg, Canada). Levofloxacin was supplied in a 5% dextrose intravenous solution (5 mg/ mL). Linezolid was supplied in a dextrose intravenous formulation (2 mg/mL).
Susceptibility and synergy testing
Susceptibility studies were conducted on both B. anthracis strains with S. aureus ATCC 25923 for quality control. MIC and MBC were determined by the microdilution broth method. 8, 9 Uninoculated CAMHB and inoculated antibiotic-free CAMHB served as controls. MBC was determined via plating 1 mL from each non-turbid well onto LB-Miller plates and incubating overnight at 378C. MBC was defined as the concentration where there was a 3 log 10 cfu/mL reduction versus the original inoculum.
Linezolid and levofloxacin synergy was determined using a chequerboard assay (dilutions ranging from 0.03 to 32 mg/L). 8, 9 Bacterial suspensions were prepared in CAMHB and inoculated into each well. Uninoculated CAMHB and inoculated antibiotic-free CAMHB served as controls. Plates were incubated overnight at 378C. The fractional inhibitory concentration index (FICI) was calculated using MICs and FICI determined from susceptibility and synergy testing were the concentrations used for the remainder of the study.
Continuous medium replacement model (CMRM)
A CMRM was used to study the response of B. anthracis to antibiotic exposure ( Figure 1 ). 11 The pump (Masterflex, Cole-Parmer, IL, USA) was set to a flow rate of 1 mL/min and calibrated according to the manufacturer's instructions. Reaction flasks (containing 250 mL of bacterial culture with no antibiotic, linezolid, levofloxacin or the combination) were placed in a 378C water bath.
Samples (1 mL each) were collected at 0, 2, 4, 6, 8, 24 and 48 h. Counts were quantified via the plate count method. 12 
Spore studies
To promote sporulation, bacterial suspensions were prepared in 14 mL of minimal medium [10% Columbia broth plus 0.1 mM MnSO 4 (CB-M)] with no antibiotic, linezolid, levofloxacin or the combination. 13 Samples (1 mL each) were taken at 0, 24 and 48 h. Spore counts were determined by the heat shock method. 14, 15 Toxin (PA83) quantification Bacterial suspensions were prepared in 100 mL of CAMHB and initial inoculum and toxin were determined. Samples (1 and 4 mL for cell and toxin quantification, respectively) were taken at 24 and 48 h. Cell counts were quantified as described above. Toxin samples were filtered through a 0.2 mm cellulose acetate filter (VWR International, Ontario) to remove all bacteria and spores. Toxin was concentrated (by a factor of 4) using Amicon Ultra-0.5 mL Centrifugal Filters (EMD Millipore, MA, USA). Filtrate was collected and PA83 quantified using an ELISA (Alpha Diagnostic, TX, USA). Samples were run in parallel with the positive recombinant controls according to the manufacturer's instructions and read at 450 nm. PA83 concentration (ng/mL) was determined using the best fit line from the standard curve ( Figure S1 , available as Supplementary data at JAC Online).
Statistical analysis
Data are expressed as the mean+SEM. The relationships of time, treatment and strain with cell counts, sporulation or toxin formation were assessed using a three-way ANOVA. Tukey's post hoc analyses were conducted on significant results. Two-way ANOVA was applied to nonsignificant results with post hoc tests for significant results.
Results
Susceptibility and synergy studies 
Growth in the CMRM
Sterne and 03-0191 controls started with 4.1+0.1 and 4.6+ 0.1 log 10 cfu/mL, respectively, and reached 5.5 log 10 cfu/mL by 48 h (Figure 2a and b) . No difference was noted between antibiotic therapies for bacterial killing. All treatments were equally effective (P, 0.001) and decreased counts to ,1 log 10 cfu/mL by 48 h.
Effect of antibiotics on sporulation
All antibiotic treatments effectively reduced sporulation (P,0.001, Figure 2c and d) . Linezolid resulted in the greatest reduction in Figure 1 . Schematic of the CMRM. CAMHB containing either no antibiotic, linezolid, levofloxacin or the combination is pumped from the medium reservoir into the reaction flask (which contains 250 mL of active bacterial culture). As 1 mL of fresh medium is pumped into the reaction flask, used medium (plus bacterial culture) is pumped out into the waste at a similar rate.
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sporulation, while the combination resulted in the lowest; however, this difference was not statistically significant.
Effect of antibiotics on PA83
Both strains started with 3 ng/mL PA83 (limit of detection). Within 48 h, the Sterne and 03-0191 controls produced 1516+797 and 1716+466 ng/mL PA83 (Figure 2e and f) .
All antibiotic treatments significantly reduced 03-0191 toxin production (P, 0.001 versus control). For Sterne, no toxin was detected for linezolid and minimal toxin was detected for the combination (P¼ 0.001 versus control), although there was still 3.4 log 10 cfu/mL after 48 h ( Figure S2 ). Levofloxacin did not have an effect on toxin production since at 24 h PA83 levels were similar to the control. Likewise, at 48 h levofloxacin toxin levels (133+38 ng/mL) were 10-fold greater than those for linezolid or the combination (P,0.030).
Discussion
Currently, in the event of an anthrax outbreak, none of the antibiotics targets the bacterium's ability to form spores or toxins. This paper describes the effect of linezolid and levofloxacin on B. anthracis Sterne and 03-0191 toxin production, sporulation and cell viability.
In accordance with initial susceptibility testing, linezolid was bacteriostatic, whereas levofloxacin was bactericidal. 4, 6 Synergy titrations indicated that the combination was synergistic or indifferent; however, in all models antagonism was observed. Linezolid resulted in the lowest increase in sporulation, while the combination resulted in the highest. Linezolid also prevented toxin production altogether, while the combination only reduced it.
Although studies have looked at the efficacy of single antimicrobials on B. anthracis sporulation in vitro, no studies have Effects of combination therapy on B. anthracis JAC assessed their effect in vivo. Several studies using Clostridium difficile have found that protein synthesis inhibitors are more effective than other antimicrobials in vivo and that in vitro efficacy has translated well into in vivo efficacy. 16, 17 It was hypothesized that the combination would be the most effective treatment since linezolid would inhibit spore and toxin production, while levofloxacin would rapidly kill the bacteria. 6 However, the results herein indicate otherwise. This discrepancy might be due to the mechanisms of action of these two drugs. 4, 6 According to previous studies, bactericidal drugs are most potent against actively growing cells. 17 Therefore, when levofloxacin and linezolid were combined the inhibition of protein synthesis by linezolid could have resulted in reduction of levofloxacin efficacy, explaining why no synergy was observed.
Despite this being the first study looking at the combined effect of linezolid and levofloxacin on B. anthracis killing, previous studies looking at other antibiotic combinations on other species have reached similar conclusions. 18, 19 It is reasonable to assume that fluoroquinolones in general when combined with protein synthesis inhibitors will not be truly synergistic.
Although the combination of linezolid and levofloxacin was antagonistic, linezolid on its own was able to kill B. anthracis, while abolishing toxin production and reducing sporulation. Since our experimental AUCs of linezolid are concordant with in vivo pharmacokinetics in humans, it is likely that linezolid may be a promising alternative for the treatment of anthrax. 20 Considering that linezolid kills slowly, in vivo studies looking at a step-wise approach using linezolid initially to stop spore and toxin production followed by levofloxacin to rapidly kill vegetative B. anthracis are recommended.
